Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug...
Dateline City: KENILWORTH, N.J. Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:...
View ArticleGSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Dateline City: LONDON & KENILWORTH, N.J. Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®...
View ArticleMerck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015...
Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal...
View ArticleMerck Statement on FDA Advisory Committee Meeting for BRIDION® (sugammadex),...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a...
View ArticleMerck Statement Regarding CUBICIN® (daptomycin for injection) Patent Litigation
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S....
View ArticleMerck to Release Findings from Integrated Analysis of Six Phase 2 and 3...
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and...
View ArticleMerck Announces Presentation of Phase 3 Results of Investigational...
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting® Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck...
View ArticleMerck Announces Presentation of Results from Two Phase 2 Studies of...
Dateline City: KENILWORTH, N.J. Merck Advances to Part B of C-CREST Phase 2 Clinical Development Program KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and...
View ArticleNew Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid...
Dateline City: KENILWORTH, N.J. First-Time Presentation of KEYTRUDA Compared to Chemotherapy in Advanced Non-Small Cell Lung Cancer From KEYNOTE-010 Study New Findings of KEYTRUDA in Novel Combinations...
View ArticleMerck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir)...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for...
View ArticleMerck to Hold Investor Briefing at 2016 ASCO Annual Meeting
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck...
View ArticleNew Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with...
Dateline City: KENILWORTH, N.J. Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as...
View ArticleNew KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in...
Dateline City: KENILWORTH, N.J. New Analysis from KEYNOTE-010, Comparing KEYTRUDA to Chemotherapy, Shows Improved Survival Benefit in Patients with Increased Levels of PD-L1 Expression KEYNOTE-001...
View ArticleNew Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating...
View ArticleNew Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the...
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating...
View ArticleUpdated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show...
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS...
View ArticleKEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent,...
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH,...
View ArticleMerck to Acquire Afferent Pharmaceuticals
Dateline City: KENILWORTH, N.J. & SAN MATEO, Calif. KENILWORTH, N.J. & SAN MATEO, Calif.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent...
View ArticleMerck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an...
Dateline City: KENILWORTH, N.J. & NEW YORK Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck...
View ArticleMerck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in...
Dateline City: KENILWORTH, N.J. Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association KENILWORTH,...
View Article
